CMPX Company Profile and Key Details

CMPX has shown sold momentum, gaining 9.6% over the past week and 34.04% over the past quarter, though year-to-date performance is up 6.33%. Short-term trend indicators are bearishly aligned (SMA20 -8.34%, SMA50 -0.29%, SMA200 43.9%). The stock’s 14-day RSI is 42.14 (neutral), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.99% below its high and over 334.59% above its low. Average 10-day trading volume of 4.07 million shares is slightly above the 3-month average of 3.03 million, indicating heightened recent market interest.

Compass Therapeutics, Inc. generated EPS of -$0.46 over the past year. Five-year average earnings growth is -104.7%. Wall Street analysts project EPS growth of -2.73% annually over the next five years. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$32.62. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $5.00. The high target offers 2531.58% upside. The low target suggests 338.6% downside. The mean target is $13.74. This offers 1105.26% upside. Compass Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 17.47%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 08, 2025.

Compass Therapeutics, Inc. (NASDAQ:CMPX) closed at $1.14 USD, losing -$0.03 (-2.99%) from the previous close of $1.17. The stock is currently within 5% of its 52-week low $1.10 and $6.88. With a market capitalization of about $204.40 million, Compass Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.84). Key stats such as the average daily volume over the past year has been around 3.40 million shares, in line with its 52-week average. Headquartered in Boston, MA, Compass Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas J. Schuetz, the company employs approximately 39 people and listed since April 05, 2021. Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials.

Compass Therapeutics, Inc. has 180.09 million shares outstanding. The public float is 132.45 million shares, elevated short interest at 27.08% of float. This equals 40.79 million shares. The short ratio is 12.77 days. Institutional investors hold 107.43% of the float. Insiders own 12.46%. OrbiMed Genesis GP LLC holds 14.69 million shares, Schuetz Thomas J. has 6.48 million shares and Sunderland Julie has 2.50 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Compass Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

Compass Therapeutics, Inc. trades at a P/E ratio of -2.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.28 suggesting the stock is closer to book value. The P/FCF stands at -3.71, also below market averages.

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are flat 6.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Compass Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.97, suggesting 1125.44% upside. Our AI forecast model points to short-term weakness (-35.96% over two weeks), a medium-term rise (177.19% over three months), and a longer-term loss (-69.3% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Compass Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -35.96%, with price expected at $0.73 by October 07, 2026, within a range of $0.61 to $0.85 3-Month Outlook: Projected rise of 177.19%, reaching $3.16 by December 22, 2026, with a range of $2.97 to $3.33. 1-Year Outlook: Projected loss of -69.3%, with price at $0.35 by September 23, 2027, within a range of $0.00 to $0.10.